Virtual Library
Start Your Search
B. Tischer
Author of
-
+
P3.02b - Poster Session with Presenters Present (ID 494)
- Event: WCLC 2016
- Type: Poster Presenters Present
- Track: Advanced NSCLC
- Presentations: 1
- Moderators:
- Coordinates: 12/07/2016, 14:30 - 15:45, Hall B (Poster Area)
-
+
P3.02b-023 - Physician Patterns of Care in Patients with EGFR Mutation+ NSCLC: An International Survey into Testing and Treatment Choice (ID 6067)
14:30 - 15:45 | Author(s): B. Tischer
- Abstract
Background:
(Applied for Late-Breaking Abstract Status) IASLC guidelines recommend EGFR mutation testing should be performed at diagnosis of advanced NSCLC to guide treatment decisions. In 2015 an international survey concluded that not all patients were tested or received test results before treatment initiation. This varied between countries and across regions. The aim of a follow-up survey in 2016 was to assess testing rates and HCP treatment choice in advanced NSCLC to identify improvements and changes compared to 2015.
Methods:
Online survey of 707 oncologists in 11 countries (Canada, China, France, Germany, Italy, Japan, South Korea, Spain, Taiwan, UK, USA) between July - August 2016. China was newly added in 2016. For better comparison with 2015 results, China was excluded from the primary results focus
Results:
Globally*, physicians requested EGFR mutation testing prior to first-line therapy of stage IIIb/IV NSCLC in 80% of patients. However, 18% of ordered tests were not received prior to deciding first-line therapy; an improvement on 2015 with 23%. Excluding histology, the main reasons for not testing prior to first-line therapy were insufficient tissue, poor performance status and long turnaround time. While turnaround time significantly reduced year-on-year (2016: 21% vs. 2015: 30%), globally* 24% of patients receive test results after more than 10 business days. Globally* 79% (2015: 80%) of patients with mutations (M+) were treated with tyrosine kinase inhibitors (TKIs), with large country variations on treatment preference (minimum 68% Germany; maximum 98% Taiwan). Prolonging of survival/extending life (54%*) was deemed the most important therapy goal in first-line treatment. 74%* of physicians stated that a clinically relevant increase in overall survival was the most important treatment attribute when choosing a first-line therapy, closely followed by an increase in progression-free survival (68%) and strong improvement of health related quality of life (66%). Perceived differences between TKIs were reported by 49% of physicians. Further detail will be presented at the congress. *Global figures excluding China
Conclusion:
While year-on-year improvements in EGFR testing rates, and availability of test results prior to first-line therapy are seen, a large proportion of EGFR M+ NSCLC patients are still not receiving targeted treatment with TKIs based on mutation status. Incomplete implementation of guidelines is still observed. The main barriers to testing, including receiving results in time, must be addressed if treatment equality for all eligible patients can be achieved. Physician education and closer guideline concordance are key steps to further improve outcomes.
